A Single-arm, Open-Label, Multicenter Phase II Study to Evaluate the Efficacy and Safety of HA121-28 Tablets in Patients With Medullary Thyroid Carcinoma (MTC)
Latest Information Update: 24 Feb 2022
At a glance
- Drugs HA121 28 (Primary)
- Indications Carcinoma; Thyroid cancer
- Focus Therapeutic Use
- Sponsors CSPC ZhongQi Pharmaceutical Technology
- 25 Jul 2021 Status changed from not yet recruiting to recruiting.
- 15 Mar 2021 New trial record